Results 191 to 200 of about 128,667 (316)

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Breastfeeding Should Not Be a Privilege. [PDF]

Ann Fam Med
Thiyagarajan D.
europepmc   +1 more source

The International Monetary System and the Theory of Monetary Systems

, 2016
openaire   +2 more sources

Financial incentives for women's cervical, breast and colorectal cancer screening adherence: systematic review and meta-analysis. [PDF]

Prev Med Rep
Lumia C, Nespoli A, Ausili D, Fumagalli S, Dumont A.   +4 more
europepmc   +1 more source

Money and the International Monetary System [PDF]

Review, 1989
openaire   +2 more sources

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Carbon footprint of a clinical biochemistry platform in a French university hospital: Identifying the main greenhouse gas emission sources. [PDF]

J Clim Chang Health
Cécile K, Margaux V, Florence R, Chrystel L, Didier B, Camille CG.   +5 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Friends with benefits: What constitutes a 'benefit' in Access and Benefit Sharing (ABS) for plant genetic resources? [PDF]

Agric Human Values
Beumer K, Roskam A.
europepmc   +1 more source

Safety concerns reported by coroners following fentanyl patch fatalities in England, Wales and Northern Ireland between 1997 and 2024

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim To identify safety concerns reported by coroners following fentanyl patch‐related deaths in England, Wales and Northern Ireland, and determine differences in coronial reporting. Methods A systematic case series linking the National Programme on Substance Use Mortality (NPSUM) and the Preventable Deaths Tracker (PDT) (https ...
Eman Mshari, Caroline S. Copeland, Georgia C. Richards   +2 more
wiley   +1 more source